Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?
No OS Benefit Over Chemotherapy
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
You may also be interested in...
Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.
Sotrovimab data could help with uptake, though the market remains challenging as infections fall. Plus RedHill presents encouraging Phase II data for oral drug to treat COVID-19 infection and inflammation after completing Phase II/III study enrollment and Japan taps its world-leading supercomputer.
In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung disease leadership.